BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30045021)

  • 1. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
    Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
    Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of quinones as novel PIM1 kinase inhibitors.
    Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
    Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
    PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
    Holder SL; Abdulkadir SA
    Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
    Grundler R; Brault L; Gasser C; Bullock AN; Dechow T; Woetzel S; Pogacic V; Villa A; Ehret S; Berridge G; Spoo A; Dierks C; Biondi A; Knapp S; Duyster J; Schwaller J
    J Exp Med; 2009 Aug; 206(9):1957-70. PubMed ID: 19687226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion.
    Eerola SK; Santio NM; Rinne S; Kouvonen P; Corthals GL; Scaravilli M; Scala G; Serra A; Greco D; Ruusuvuori P; Latonen L; Rainio EM; Visakorpi T; Koskinen PJ
    Cell Commun Signal; 2019 Nov; 17(1):148. PubMed ID: 31730483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
    Morishita D; Takami M; Yoshikawa S; Katayama R; Sato S; Kukimoto-Niino M; Umehara T; Shirouzu M; Sekimizu K; Yokoyama S; Fujita N
    J Biol Chem; 2011 Jan; 286(4):2681-8. PubMed ID: 21062737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.
    Magistroni V; Mologni L; Sanselicio S; Reid JF; Redaelli S; Piazza R; Viltadi M; Bovo G; Strada G; Grasso M; Gariboldi M; Gambacorti-Passerini C
    PLoS One; 2011; 6(11):e28162. PubMed ID: 22140532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice.
    Ni F; Gong Y; Li L; Abdolmaleky HM; Zhou JR
    PLoS One; 2012; 7(6):e38802. PubMed ID: 22693649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
    Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
    Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
    Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
    J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 and PTEN are involved in the anti-metastatic regulation of anethole in DU145 prostate cancer cells.
    Rhee YH; Chung PS; Kim SH; Ahn JC
    Biochem Biophys Res Commun; 2014 May; 447(4):557-62. PubMed ID: 24525130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.
    Zemskova MY; Song JH; Cen B; Cerda-Infante J; Montecinos VP; Kraft AS
    Cell Signal; 2015 Jan; 27(1):135-46. PubMed ID: 25451079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors.
    Anizon F; Shtil AA; Danilenko VN; Moreau P
    Curr Med Chem; 2010; 17(34):4114-33. PubMed ID: 20939820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.